For most of the twentieth century, inflammation was thought to resolve passively — the chemical signals that called immune cells to a wound were simply assumed to dilute away as the threat subsided. Charles Serhan’s laboratory at Harvard overturned that assumption in the early 2000s by identifying a distinct family of lipid mediators, biosynthesized from omega-3 fatty acids, that actively switch off inflammation and drive tissue repair. These specialized pro-resolving mediators (SPMs) represent a fundamental reframing of inflammation as a biphasic program with a dedicated stop signal.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are a class of endogenous lipid autacoids enzymatically derived from polyunsaturated fatty acids — primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with a smaller contribution from arachidonic acid (lipoxins) and n-3 docosapentaenoic acid. The major SPM families include resolvins (E-series from EPA and D-series from DHA), protectins (from DHA), maresins (from DHA via macrophage 12-lipoxygenase), and lipoxins (from arachidonic acid). Serhan and colleagues first characterized these mediators in self-resolving inflammatory exudates and demonstrated they act in the picogram-to-nanogram range to limit neutrophil infiltration and promote macrophage clearance of apoptotic cells.[1]
Critically, SPMs are not anti-inflammatory in the classical sense — they do not block the initiation of inflammation. Instead, they activate a distinct genetic and cellular program that terminates the inflammatory response and restores tissue homeostasis. This distinction has therapeutic significance: NSAIDs and corticosteroids suppress inflammation but can impair resolution, whereas SPMs accelerate resolution without immunosuppression.[2]
How SPMs Are Biosynthesized
The Lipoxygenase Cascade: SPM biosynthesis is initiated by sequential oxygenation of EPA or DHA by lipoxygenase (LOX) and cyclooxygenase-2 (COX-2) enzymes — often involving transcellular biosynthesis where intermediates produced by one cell type (e.g., a neutrophil) are further metabolized by another (e.g., an endothelial cell or platelet). For D-series resolvins, DHA is first converted by 15-LOX to 17-HpDHA, then further metabolized by 5-LOX to yield resolvins D1 through D6.[1]
Aspirin-Triggered Epimers: One of the most clinically relevant discoveries was that aspirin acetylates COX-2 rather than fully inhibiting it, switching the enzyme’s output to produce 18R-HEPE from EPA and 17R-HDHA from DHA. These precursors are then converted by 5-LOX into aspirin-triggered resolvins (AT-RvD and AT-RvE series), which are more resistant to inactivation and carry potent pro-resolving activity. This provides a molecular explanation for some of aspirin’s pleiotropic benefits beyond platelet inhibition.[3]
Maresin Biosynthesis: Maresins (macrophage mediators in resolving inflammation) are produced primarily by macrophages via 12-LOX, which converts DHA to 13S,14S-epoxy-maresin and subsequently maresin 1 (MaR1). Maresins are particularly associated with the macrophage phenotype switch from M1 (pro-inflammatory) to M2 (pro-resolving) and with tissue regeneration signaling.[4]
Protectin Synthesis: Protectin D1 (also called neuroprotectin D1 when produced in neural tissue) is generated from DHA via 15-LOX to form a 16,17-epoxide intermediate, which is then hydrolyzed to PD1. Protectins are notable for their activity in neural tissue, retina, and resolving viral inflammation.
Mechanisms of Action
G-Protein Coupled Receptor Signaling: SPMs act through specific G-protein coupled receptors. RvD1 binds ALX/FPR2 (also the lipoxin A4 receptor) and GPR32; RvE1 binds ChemR23 (ERV1) and antagonizes the leukotriene B4 receptor BLT1; MaR1 binds LGR6. These receptor interactions produce nanomolar-potency effects on neutrophil chemotaxis, macrophage phagocytosis of apoptotic cells (efferocytosis), and cytokine production.[2]
Neutrophil Trafficking and Efferocytosis: A hallmark SPM action is the limitation of further neutrophil infiltration combined with stimulation of macrophage clearance of apoptotic neutrophils. This efferocytosis is essential for resolution — accumulation of uncleared apoptotic cells perpetuates inflammation and is implicated in chronic inflammatory diseases. RvD1 and RvE1 increase efferocytosis efficiency several-fold in experimental models.[2]
Cytokine Class Switching: SPMs do not simply lower cytokine output; they shift the cytokine profile. Treatment reduces TNF-α, IL-6, IL-1β, and IL-8 while increasing IL-10 and TGF-β, supporting transition to the repair phase.
Clinical Evidence
Endogenous SPM Production from Fish Oil: A randomized trial by Mas and colleagues demonstrated that oral supplementation with EPA/DHA in healthy humans elevated plasma levels of 18-HEPE, 17-HDHA, and several E- and D-series resolvin precursors in a dose-dependent fashion, providing direct evidence that dietary omega-3 intake feeds SPM biosynthesis pathways.[5]
Periodontal Disease: Resolvin E1 has been studied extensively in periodontal disease, where chronic neutrophilic inflammation drives bone loss. Topical RvE1 in rabbit periodontitis models prevented and reversed alveolar bone loss and normalized neutrophil function — among the strongest pre-clinical translational data for an SPM.[3]
Cardiovascular and Metabolic Disease: SPM levels are reduced in atherosclerotic plaques compared with stable vascular tissue, and in obese individuals with metabolic syndrome compared with lean controls. The ratio of pro-resolving to pro-inflammatory lipid mediators in plaque tissue correlates with plaque stability, suggesting a resolution deficit contributes to chronic vascular inflammation.[2]
Inflammatory and Neurodegenerative Disease: Reduced SPM levels have been documented in patients with rheumatoid arthritis, inflammatory bowel disease, and Alzheimer’s disease. In Alzheimer’s specifically, hippocampal levels of protectin D1 and resolvin D1 are decreased relative to age-matched controls, and in vitro studies show SPMs enhance microglial phagocytosis of amyloid-β.[4]
Safety Profile
Endogenous SPMs and their precursors derived from dietary EPA/DHA have an extensive safety record through decades of fish oil supplementation research. Because SPMs work through specific receptor agonism at nanomolar concentrations rather than broad enzyme inhibition, they do not appear to cause the immunosuppression seen with corticosteroids or the gastrointestinal and renal toxicity of NSAIDs.
Synthetic SPM analogs are in early clinical development, with phase I and phase II studies of resolvin E1 analogs for dry eye disease and periodontal disease completed without major safety signals. Because SPMs do not block inflammation initiation, theoretical risk of impaired host defense appears low — and animal models actually show enhanced bacterial clearance in sepsis with SPM treatment, attributed to improved phagocytic function rather than suppressed immunity.[2]
The most practical clinical lever remains substrate availability: adequate EPA/DHA intake (whether dietary or supplemented) is required for endogenous SPM biosynthesis. Patients on high-dose aspirin will preferentially generate aspirin-triggered SPM epimers, which may explain part of aspirin’s anti-inflammatory benefit beyond platelet effects.
SPMs vs Other Anti-Inflammatory Approaches
vs NSAIDs: NSAIDs inhibit COX enzymes and reduce prostaglandin synthesis — blocking the initiation of inflammation. However, this can paradoxically impair resolution because COX-2 is required for the biosynthesis of certain SPMs and aspirin-triggered lipid mediators. Selective COX-2 inhibitors in particular may delay resolution in some contexts.
vs Corticosteroids: Glucocorticoids broadly suppress transcription of pro-inflammatory genes via NF-κB and AP-1 inhibition. They are highly effective but immunosuppressive and catabolic. SPMs operate through agonism rather than suppression and do not produce the metabolic, skeletal, or immune side effects of chronic steroid use.
vs Fish Oil Alone: EPA/DHA supplementation provides substrate for SPM production but yields highly variable plasma SPM concentrations depending on individual lipoxygenase expression, genetic polymorphisms, and inflammatory state. Direct SPM administration bypasses this biosynthetic variability — though for most patients, optimizing omega-3 intake remains the most accessible intervention.[5]
vs Biologic Anti-Cytokine Therapy: Biologics like TNF-α inhibitors and IL-6 receptor antagonists block specific cytokines but do not actively promote resolution or tissue repair. Combination strategies — biologic suppression of acute inflammation paired with SPM-mediated resolution — represent an active area of translational research.
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Levy BD. “Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.” Journal of Clinical Investigation. 2018;128(7):2657-2669.
- Hasturk H, Kantarci A, Goguet-Surmenian E, et al. “Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo.” Journal of Immunology. 2007;179(10):7021-7029.
- Serhan CN, Yang R, Martinod K, et al. “Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.” Journal of Experimental Medicine. 2009;206(1):15-23.
- Mas E, Croft KD, Zahra P, et al. “Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation.” Clinical Chemistry. 2012;58(10):1476-1484.
